Moringa oleifera Lam. Seed Lectin (WSMoL) Reduces Visceral Adiposity, Dyslipidemia, Hyperglycemia, and Systemic Inflammation in Mice with a Metabolic Syndrome-like Condition

Abstract

Moringa oleifera Lam. seeds contain lectins that exhibit interesting bioactive properties, but their effects on metabolic syndrome (MetS) remain poorly understood. This work evaluated the effects of the water-soluble lectin from M. oleifera seeds (WSMoL) on metabolic, inflammatory, and histopathological alterations in a mouse model of MetS-like features. Male Swiss mice were fed a high-fat diet plus condensed milk solution for 11 weeks. Animals then received phosphate-buffered saline (negative control), orlistat (40 mg/kg), or WSMoL (1, 2, or 4 mg/kg, i.p.) for 14 days. A healthy group (Sham) received standard chow. The MetS-like protocol induced obesity, hyperglycemia, dyslipidemia, visceral adiposity, and systemic inflammation. WSMoL improved metabolic parameters at all doses, reducing visceral fat, attenuating hyperglycemia, and improving the lipid profile. It also decreased pro-inflammatory cytokines (IL-2, IFN-γ, TNF-α, and IL-6) while increasing IL-10 levels. WSMoL prevented hepatic steatosis and renal lipid accumulation, although inflammatory and degenerative tissue changes persisted. The 4 mg/kg dose showed efficacy but was associated with elevated AST and more frequent inflammatory alterations. In conclusion, WSMoL mitigated key features of MetS-like condition, although incomplete tissue recovery and signs of organ stress at the highest dose warrant caution regarding its potential therapeutic use.